Biological Assembly 1  

 3D View: Structure | 1D-3D View | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 43.05 kDa 
• Atom Count: 3003 
• Modelled Residue Count: 344 
• Deposited Residue Count: 372 
• Unique protein chains: 1

1OZ1

P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR

• PDB DOI: 10.2210/pdb1OZ1/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2003-04-07 Released: 2003-09-23 
• Deposition Author(s): Lovejoy, B., Villasenor, A., Browner, M., Dunten, P.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.251 
• R-Value Work: 0.201 
• R-Value Observed: 0.204 

Literature

Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.

Trejo, A., Arzeno, H., Browner, M., Chanda, S., Cheng, S., Comer, D.D., Dalrymple, S.A., Dunten, P., Lafargue, J., Lovejoy, B., Freire-Moar, J., Lim, J., Mcintosh, J., Miller, J., Papp, E., Reuter, D., Roberts, R., Sanpablo, F., Saunders, J., Song, K., Villasenor, A., Warren, S.D., Welch, M., Weller, P., Whiteley, P.E., Zeng, L., Goldstein, D.M.

(2003) J Med Chem 46: 4702-4713

• PubMed: 14561090 
• DOI: 10.1021/jm0301787
• Primary Citation of Related Structures:  
  1OZ1


• PubMed Abstract: 
  

Inhibition of the biosynthesis of proinflammatory cytokines such as tumor necrosis factor and interleukin-1 via p38 has been an approach toward the development of a disease modifying agent for the treatment of chronic inflammation and autoimmune diseases. The development of a new core structure of p38 inhibitors, 3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrolo[3,2-b] pyridine, is described. X-ray crystallographic data of the lead bound to the active site of p38 was used to guide the optimization of the series. Specific focus was placed on modulating the physical properties of the core while maintaining potent inhibition of p38. These efforts identified 42c as a potent inhibitor of p38, which also possessed the required physical properties worthy of advanced studies.

---

Organizational Affiliation: 

Department of Medicinal Chemistry, Roche Palo Alto LLC, 3431 Hillview Avenue, R6-201, Palo Alto, California 94304, USA. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Mitogen-activated protein kinase 14	A	372	Homo sapiens	Mutation(s): 0  Gene Names: MAPK14 OR CSBP1 OR CSBP2 OR CSBP OR MXI2, MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A EC: 2.7.1.37 (PDB Primary Data), 2.7.11.24 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens) Explore Q16539  Go to UniProtKB:  Q16539
PHAROS:  Q16539 GTEx:  ENSG00000112062

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
FPH	B [auth A]	3-(4-FLUOROPHENYL)-2-PYRIDIN-4-YL-1H-PYRROLO[3,2-B]PYRIDIN-1-OL C18 H12 F N3 O ZSMYZLKEZDYVPI-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
FPH	Binding MOAD:  1OZ1	IC50: 6.5 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.251 
• R-Value Work: 0.201 
• R-Value Observed: 0.204 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 45.405	α = 90
b = 85.454	β = 90
c = 125.841	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
DENZO	data reduction
SCALEPACK	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2003-04-07 
• Released Date: 2003-09-23 
Deposition Author(s): Lovejoy, B., Villasenor, A., Browner, M., Dunten, P.

Revision History  

• Version 1.0: 2003-09-23
  Type: Initial release
  
• Version 1.1: 2008-04-29
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance